Cover Image
市場調查報告書

Abilify(精神分裂症):市場預測與分析

Abilify (Schizophrenia) - Forecast and Market Analysis to 2022

出版商 GlobalData 商品編碼 299172
出版日期 內容資訊 英文 44 Pages
訂單完成後即時交付
價格
Back to Top
Abilify(精神分裂症):市場預測與分析 Abilify (Schizophrenia) - Forecast and Market Analysis to 2022
出版日期: 2014年02月28日 內容資訊: 英文 44 Pages
簡介

大塚製藥所開發的Abilify(Aripiprazole),是具有多巴胺D2受體的部分致效劑性質的喹諾酮哌啶衍生物,因為這個性質,讓它在許多精神分裂症治療藥中建立起獨特的地位。多巴胺D2受體的部分致效劑具有可調節多巴胺分泌量有所變動的區域(精神分裂症腦的中腦邊緣區及中腦皮質區等)上多巴胺的活動的作用。

本報告提供精神分裂症治療藥之一──Abilify的全球市場相關分析,提供精神分裂症概要和治療方法,Abilify的商品資訊(特色·功效·安全性等)和競爭力,競爭的企業·藥品概要,全球主要國家的市場販售額預測(今後10年份)等調查,並將結果概述為以下內容。

第1章 目錄

第2章 簡介

  • 分析概要
  • 相關分析
  • 預定發行的相關分析

第3章 疾病概要

  • 病因與病情
    • 病因
    • 病理
  • 症狀

第4章 疾病的管理

  • 診斷
    • 主觀的評估
    • 疾病的分類
  • 治療方法概要
    • 治療精神分裂症相關的急性激越症狀
    • 精神分裂症的維持療法

第5章 競爭企業的評估

  • 概要
  • 競爭企業的策略性評估

第6章 關於Abilify(Aripiprazole)

  • 概要
  • 急性治療藥的功效
  • 維持治療藥的功效
  • 安全性
  • SWOT分析
  • 預測

第7章 附錄

圖表一覽

目錄
Product Code: GDHC355DFR

Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, auditory or visual hallucinations, are often accompanied by fixed, false, and often paranoid beliefs, called delusions. These two features are often combined with learning and cognitive deficits. WHO experts have estimated that roughly 24 million people are affected by schizophrenia worldwide. While the arrival of atypical antipsychotics has greatly expanded pharmacologic treatment options over the past two decades, the current drug market does not treat the negative and cognitive symptoms that are associated with the disease. GlobalData expects that the growing popularity of long-acting injectable (LAI) antipsychotics, along with the arrival of novel treatments that achieve higher efficacy in negative- and cognitive-predominant patients, will serve to stimulate growth in the marketplace over the forecast period. Country-specific treatment recommendations and policy implementation will be an essential metric for determining future mental health services in the 7MM.

Otsuka's Abilify (aripiprazole) is a quinolone piperidine derivative with partial agonist properties at the D2 dopaminergic receptor. By acting as a partial agonist at this dopamine receptor subtype, Abilify presents a unique mechanism within the schizophrenia drug portfolio: partial D2 agonism modulates dopaminergic activity in areas where dopamine may be high or low, such as in the mesolimbic and mesocortical areas of the schizophrenic brain.

Scope

  • Overview of Schizophrenia, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Abilify including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Abilify for the top seven countries from 2012 to 2022.
  • Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Schizophrenia
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Abilify performance
  • Obtain sales forecast for Abilify from 2012-2022 in the top seven countries (the US, France, Germany, Italy, Spain, the UK and Japan)

Table of Contents

1. Table of Contents

  • 1.1. List of Tables

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Symptoms

4. Disease Management

  • 4.1. Diagnosis
    • 4.1.1. Subjective Assessments
    • 4.1.2. Disease Subtypes
  • 4.2. Treatment Overview
    • 4.2.1. Treatment of Acute Agitation Associated with Schizophrenia
    • 4.2.2. Maintenance Treatment of Schizophrenia

5. Competitive Assessment

  • 5.1. Overview
  • 5.2. Strategic Competitor Assessment

6. Abilify (aripiprazole)

  • 6.1. Overview
  • 6.2. Efficacy as an Acute Treatment
  • 6.3. Efficacy as a Maintenance Treatment
  • 6.4. Safety
  • 6.5. SWOT Analysis
  • 6.6. Forecast

7. Appendix

  • 7.1. Bibliography
  • 7.2. Abbreviations
  • 7.3. Methodology
  • 7.4. Forecasting Methodology
    • 7.4.1. Diagnosis and Treatment Rates
    • 7.4.2. Adherence Rates
    • 7.4.3. General Pricing Assumptions
    • 7.4.4. Drug Assumptions
    • 7.4.5. Generic Erosion
  • 7.5. Key Opinion Leaders
  • 7.6. About the Authors
    • 7.6.1. Author
    • 7.6.2. Reviewers
    • 7.6.3. Global Head of Healthcare
  • 7.7. About GlobalData
  • 7.8. Disclaimer

List of Tables

  • Table 1: Symptom Clusters of Schizophrenia
  • Table 2: Common Subjective Rating Scales Employed in Schizophrenia Diagnosis
  • Table 3: Development-Based Classification of Antipsychotic Drugs
  • Table 4: Receptor Binding Profiles of Atypical Antipsychotics
  • Table 5: Guidelines for the Treatment of Schizophrenia
  • Table 6: Leading Branded Treatments for Schizophrenia, 2013
  • Table 7: Strategic Competitor Assessment of the Marketed Products in Schizophrenia, 2014
  • Table 8: Product Profile - Abilify
  • Table 9: Abilify SWOT Analysis, 2014
  • Table 10: Global Sales Forecast ($m) for Abilify, 2012-2022
Back to Top